{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:38:46Z","timestamp":1787809126880,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In advanced non-small cell lung cancer (NSCLC), nivolumab plus ipilimumab with platinum-based chemotherapy (NIC) and pembrolizumab with platinum-based chemotherapy (PC) are commonly used treatment options. We conducted a single-center retrospective analysis comparing the two options under real-world conditions in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected data from patients whose treatment was initiated between July 2018 and June 2023. Primary endpoints were overall survival and safety. Categorical data were compared using the chi-squared test or Fisher\u2019s exact test. Overall survival was compared using the Kaplan\u2013Meier method and the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      200 patients, 77 treated with NIC and 123 treated with PC, were included. Baseline characteristics were unbalanced with significantly more older, squamous, and PD-L1-negative cases in the NIC group. Median overall survival (OS) and time to treatment discontinuation (TTD) were not significantly different in the NIC and PC groups (13.6 vs. 14.1\u00a0months \/ 5.8 vs. 6.2\u00a0months). Clinically significant adverse events (AEsi), related treatment discontinuations, and treatment-related deaths also did not differ significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.885\/\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.000\/\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.709). There were more immune-related AEsi in the NIC group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and more chemo-related AEsi in the PC group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NIC and PC seem to be equally supportable options in the treatment of advanced NSCLC. Further analyses are needed to validate our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-025-04244-4","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:22:52Z","timestamp":1769847772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2433-5240","authenticated-orcid":false,"given":"Moritz","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-284X","authenticated-orcid":false,"given":"Alexander","family":"Freiherr von Hammerstein-Equord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-6909","authenticated-orcid":false,"given":"Stefan","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-6052","authenticated-orcid":false,"given":"Achim","family":"Rittmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"3","key":"4244_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4244_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, Manraj SS, Kamate B, Omonisi A, Bray F (2023) Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol 24(11):1206\u20131218. https:\/\/doi.org\/10.1016\/S1470-2045(23)00444-8. (Epub 2023 Oct 11 PMID: 37837979)","journal-title":"Lancet Oncol"},{"issue":"12","key":"4244_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E (2021) Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the USA. JAMA Oncol 7(12):1824\u20131832. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4932. PMID: 34673888; PMCID: PMC8532041","journal-title":"JAMA Oncol"},{"issue":"12","key":"4244_CR4","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1016\/S2468-2667(21)00157-2","volume":"6","author":"H Zeng","year":"2021","unstructured":"Zeng H, Ran X, An L, Zheng R, Zhang S, Ji JS, Zhang Y, Chen W, Wei W, He J, HBCR Working Group (2021) Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Pub Health. 6(12):e877\u2013e887. https:\/\/doi.org\/10.1016\/S2468-2667(21)00157-2","journal-title":"Lancet Pub Health."},{"issue":"6","key":"4244_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol 40(6):586\u2013597. https:\/\/doi.org\/10.1200\/JCO.21.01497","journal-title":"J Clin Oncol"},{"key":"4244_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","volume":"186","author":"M Mathew","year":"2018","unstructured":"Mathew M, Enzler T, Shu CA, Rizvi NA (2018) Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther 186:130\u2013137. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.003. (Epub 2018 Jan 31 PMID: 29352857)","journal-title":"Pharmacol Ther"},{"issue":"22","key":"4244_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) KEYNOTE-189 investigators pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005. (Epub 2018 Apr 16 PMID: 29658856)","journal-title":"N Engl J Med"},{"issue":"21","key":"4244_CR8","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, Hermes B, \u00c7ay \u015eenler F, Cs\u0151szi T, F\u00fcl\u00f6p A, Rodr\u00edguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM (2018) KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379(21):2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865. (Epub 2018 Sep 25 PMID: 30280635)","journal-title":"N Engl J Med"},{"key":"4244_CR9","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, P\u00e9rol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial."},{"issue":"4","key":"4244_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M (2023) ESMO Guidelines Committee Electronic address: clinicalguidelines@esmo.org on-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34(4):358\u2013376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013. (Epub 2023 Jan 17 PMID: 36669645)","journal-title":"Ann Oncol"},{"issue":"1","key":"4244_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00262-023-03583-4","volume":"73","author":"K Matsumoto","year":"2024","unstructured":"Matsumoto K, Shiroyama T, Tamiya M, Minami T, Kinehara Y, Tamiya A, Suga Y, Kuge T, Mori M, Suzuki H, Tobita S, Ueno K, Namba Y, Tetsumoto S, Niki T, Morimura O, Osa A, Nishino K, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A (2024) Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study. Cancer Immunol Immunother 73(1):4. https:\/\/doi.org\/10.1007\/s00262-023-03583-4. PMID: 38175294; PMCID: PMC10766714","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"4244_CR12","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/1759-7714.15304","volume":"15","author":"A Kaneko","year":"2024","unstructured":"Kaneko A, Kobayashi N, Miura K, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Watanabe K, Horita N, Hara Y, Kudo M, Miyazawa N, Kaneko T (2024) Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer. Thorac Cancer 15(15):1208\u20131217. https:\/\/doi.org\/10.1111\/1759-7714.15304","journal-title":"Thorac Cancer"},{"issue":"11","key":"4244_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-2600(24)00185-1","volume":"12","author":"Y Shiraishi","year":"2024","unstructured":"Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I (2024) Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. Lancet Respir Med 12(11):877\u2013887. https:\/\/doi.org\/10.1016\/S2213-2600(24)00185-1. (Epub 2024 Aug 16 PMID: 39159638)","journal-title":"Lancet Respir Med"},{"issue":"10","key":"4244_CR14","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3390\/cancers16101825","volume":"16","author":"W Shalata","year":"2024","unstructured":"Shalata W, Maimon Rabinovich N, Agbarya A, Yakobson A, Dudnik Y, Abu Jama A, Cohen AY, Shalata S, Abu Hamed A, Ilan Ber T, Machluf O, Shoham Levin G, Meirovitz A (2024) Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status. Cancers (Basel). 16(10):1825. https:\/\/doi.org\/10.3390\/cancers16101825","journal-title":"Cancers (Basel)."},{"issue":"2","key":"4244_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"2","key":"4244_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008189","volume":"12","author":"DP Carbone","year":"2024","unstructured":"Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M (2024) Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. J Immunother Cancer 12(2):e008189. https:\/\/doi.org\/10.1136\/jitc-2023-008189. PMID: 38346853; PMCID: PMC10862253","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4244_CR17","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Kurata T, Gray JE, Schwarzenberger P, Jensen E, Pietanza MC, Rodr\u00edguez-Abreu D (2023) Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 41(11):1992\u20131998. https:\/\/doi.org\/10.1200\/JCO.22.01989","journal-title":"J Clin Oncol"},{"issue":"11","key":"4244_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, Rodr\u00edguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L (2023) Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol 41(11):1999\u20132006. https:\/\/doi.org\/10.1200\/JCO.22.01990","journal-title":"J Clin Oncol"},{"issue":"11","key":"4244_CR19","doi-asserted-by":"publisher","first-page":"698199","DOI":"10.3389\/fonc.2021.698199","volume":"13","author":"P Jiang","year":"2021","unstructured":"Jiang P, Mao Z, Wang Q, Jia X, Geng L, Xu H, Jiang L, Yang C, Jiao M, Guo H (2021) n Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer. Front Oncol 13(11):698199. https:\/\/doi.org\/10.3389\/fonc.2021.698199. PMID: 34589422; PMCID: PMC8473819","journal-title":"Front Oncol"},{"issue":"7","key":"4244_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","volume":"16","author":"L Liu","year":"2021","unstructured":"Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, Li S, Xue P, Wang G, Sun Y, Du X, Zhang X, Ma Z, Wang J (2021) Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. J Thorac Oncol 16(7):1099\u20131117. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.016. (Epub 2021 Apr 8 PMID: 33839365)","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4244_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100465","volume":"7","author":"MA Siciliano","year":"2022","unstructured":"Siciliano MA, Carid\u00e0 G, Ciliberto D, d\u2019Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P (2022) Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. ESMO Open 7(3):100465. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100465","journal-title":"ESMO Open"},{"key":"4244_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114006","volume":"202","author":"A Leonetti","year":"2024","unstructured":"Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, Vita E, Gelsomino F, De Giglio A, Gelibter A, Siringo M, Mazzoni F, Caliman E, Genova C, Bertolini F, Guaitoli G, Passiglia F, Delcuratolo MD, Montrone M, Cerea G, Pasello G, Roca E, Belluomini L, Cecere FL, Guida A, Manzo A, Adamo V, Rastelli F, Bulotta A, Citarella F, Toschi L, Zoratto F, Cortinovis DL, Berardi R, Follador A, Carta A, Camerini A, Salerno F, Silva RR, Baldini E, Cortellini A, Brighenti M, Santoni M, Malorgio F, Caminiti C, Tiseo M (2024) Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. Eur J Cancer 202:114006. https:\/\/doi.org\/10.1016\/j.ejca.2024.114006","journal-title":"Eur J Cancer"},{"issue":"4","key":"4244_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10147-022-02120-0","volume":"27","author":"T John","year":"2022","unstructured":"John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S (2022) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. Int J Clin Oncol 27(4):695\u2013706. https:\/\/doi.org\/10.1007\/s10147-022-02120-0","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"4244_CR24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","volume":"32","author":"D Rodr\u00edguez-Abreu","year":"2021","unstructured":"Rodr\u00edguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, D\u00f3mine M, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC (2021) Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol 32(7):881\u2013895. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.008","journal-title":"Ann Oncol"},{"issue":"10","key":"4244_CR25","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazi\u00e8res J, Hermes B, Cicin I, Medgyasszay B, Rodr\u00edguez-Cid J, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15(10):1657\u20131669. https:\/\/doi.org\/10.1016\/j.jtho.2020.06.015. (Epub 2020 Jun 26 PMID: 32599071)","journal-title":"J Thorac Oncol"},{"key":"4244_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871675","author":"Y Asano","year":"2022","unstructured":"Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Saito S, Sone T, Kasahara K, Tsuchiya H (2022) The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.871675","journal-title":"Front Oncol"},{"issue":"5","key":"4244_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X. (Erratum in: Lancet Respir Med. 2021 Mar;9(3):e29. Doi: 10.1016\/S2213-2600(21)00012-6.)","journal-title":"Lancet Respir Med"},{"issue":"2","key":"4244_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","volume":"158","author":"K Tang","year":"2022","unstructured":"Tang K, Seo J, Tiu BC, Le TK, Pahalyants V, Raval NS, Ugwu-Dike PO, Zubiri L, Naranbhai V, Carrington M, Gusev A, Reynolds KL, LeBoeuf NR, Asgari MM, Kwatra SG, Semenov YR (2022) Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy. JAMA Dermatol 158(2):189\u2013193. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5476. PMID: 35019948; PMCID: PMC8756357","journal-title":"JAMA Dermatol"},{"issue":"5","key":"4244_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","volume":"88","author":"S Zhang","year":"2023","unstructured":"Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR (2023) Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study. J Am Acad Dermatol 88(5):1024\u20131032. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.048","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"4244_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner F, Bomze D, Diem S, Ali OH, F\u00e4ssler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, L\u00e4ubli H, Zippelius A, Hartmann F, Cheng HW, H\u00f6nger G, Recher M, Goldman J, Cozzio A, Fr\u00fch M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L (2019) Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 5(7):1043\u20131047. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0402","journal-title":"JAMA Oncol"},{"issue":"2","key":"4244_CR31","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/j.sapharm.2021.07.006","volume":"18","author":"MJ Barnett","year":"2022","unstructured":"Barnett MJ, Doroudgar S, Khosraviani V, Ip EJ (2022) Multiple comparisons: To compare or not to compare, that is the question. Res Social Adm Pharm 18(2):2331\u20132334. https:\/\/doi.org\/10.1016\/j.sapharm.2021.07.006. (Epub 2021 Jul 8 PMID: 34274218)","journal-title":"Res Social Adm Pharm"}],"updated-by":[{"DOI":"10.1007\/s00262-026-04360-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04244-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:56:36Z","timestamp":1775490996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04244-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4244"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04244-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-026-04360-9","URL":"https:\/\/doi.org\/10.1007\/s00262-026-04360-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was approved by the responsible ethics board (University Medical Center G\u00f6ttingen, file number 4\/10\/23).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients consented to the use of their data for research purposes during their first stay at Lungenfachklinik Immenhausen. This consent provided them with the possibility to withdraw it at any time without giving reasons.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"65"}}